PLANO, Texas, June 16, 2011 /PRNewswire/ -- MacuCLEAR, Inc., a specialty clinical stage pharmaceutical company focused on discovering and developing novel solutions for vascular disorders of the eye, announced today that Philip G. Ralston, president and CEO, will be presenting at OneMedForum New York 2011 on Thursday, June 23, 2011 at 11:30 a.m. EDT at The Roosevelt Hotel in New York City.
OneMedForum will focus on critical success factors for building companies internationally. In addition to presentations by more than 70 emerging medical technology companies, delegates will gain insights in the critical areas of regulatory approval, reimbursement and distribution and sales organizations in the EU and U.S.
Concurrently, Mr. Ralston will also present at the 2011 BIO Business Forum during the annual BIO International Convention at the Walter E. Washington Convention Center in Washington, D.C. Mr. Ralston's presentation will be given on Wednesday, June 29, 2011 at 9:15 a.m. EDT in the Adams Morgan Room. The presentation will include an overview of the company with emphasis on the lead proprietary compound, MC-1101, which is being developed for the treatment of the dry form of age-related macular degeneration (AMD).
The BIO Business Forum is a unique platform for biotechnology and pharmaceutical companies, academic research institutions and investors from around the world to gather and discuss strategic opportunities. This forum is featured within the BIO International Convention, the largest global event for the biotechnology industry, offering networking and partnering opportunities with policymakers, scientists, CEOs and newsmakers and hundreds of sessions covering biotech trends, policy issues and technological innovations.
About MacuCLEAR, Inc.
MacuCLEAR, Inc. is a clinical-stage specialty pharmaceutical company focused on developing innovative treatments for vascular and retinal di
|SOURCE MacuCLEAR, Inc.|
Copyright©2010 PR Newswire.
All rights reserved